Market Overview

Sanofi's Genzyme to Present New Data from AUBAGIO and LEMTRADATM

Genzyme,
a Sanofi company (NYSE: SNY), announced today
new data from Genzyme's clinical development programs for AUBAGIO®
(teriflunomide) and LEMTRADATM (alemtuzumab) will be
presented at the 28th Congress of the European Committee for
Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France,
October 10-13.

“The data to be presented at ECTRIMS are a reflection not only of the
comprehensive clinical development programs supporting AUBAGIO and
LEMTRADA, but of the unique commitment and substantial progress Genzyme
has made to date in bringing forward differentiated therapies in
multiple sclerosis,” said Genzyme CEO and President, David Meeker.

Once-daily, oral AUBAGIO is

See full press release

Posted-In: News Guidance Management Global

 

Related Articles (SNY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters